Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2019

01-08-2019 | PRECLINICAL STUDIES

Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma

Authors: Peng-jin Mei, Jin Bai, Fa-an Miao, Zhong-lin Li, Chen Chen, Jun-nian Zheng, Yue-chao Fan

Published in: Investigational New Drugs | Issue 4/2019

Login to get access

Summary

Recently, XRCC1 polymorphisms were reported to be associated with glioma in Chinese population. However, only a few studies reported on the XRCC1 expression, and cancer progression. In this study, we investigated whether XRCC1 plays a role in glioma pathogenesis. Using the tissue microarray technology, we found that XRCC1 expression is significantly decreased in glioma compared with tumor adjacent normal brain tissue (P < 0.01, χ2 test) and reduced XRCC1 staining was associated with WHO stages (P < 0.05, χ2 test). The mRNA and protein levels of XRCC1 were significantly downregulated in human primary glioma tissues (P < 0.001, χ2 test). We also found that XRCC1 was significantly decreased in glioma cell lines compared to normal human astrocytes (P < 0.01, χ2 test). Overexpression of XRCC1 dramatically reduced the proliferation and caused cessation of cell cycle. The reduced cell proliferation is due to G1 phase arrest as cyclin D1 is diminished whereas p16 is upregulated. We further demonstrated that XRCC1 overexpression suppressed the glioma cell migration and invasion abilities by targeting MMP-2. In addition, we also found that overexpression of XRCC1 sharply inhibited angiogenesis, which correlated with down-regulation of VEGF. The data indicate that XRCC1 may be a tumor suppressor involved in the progression of glioma.
Literature
1.
2.
Li Y et al (2017) Human fibulin-3 protein variant expresses anti-cancer effects in the malignant glioma extracellular compartment in intracranial xenograft models. Oncotarget 8(63):106311–106323PubMedPubMedCentral
3.
Hundsberger T, Reardon DA, Wen PY (2017) Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther 17(6):507–515CrossRefPubMed
4.
Pronin S, Koh CH, Hughes M (2017) Effects of ultraviolet radiation on Glioma: systematic review. J Cell Biochem 118(11):4063–4071CrossRefPubMed
5.
Wood RD, Mitchell M, Sgouros J, Lindahl T (2001) Human DNA repair genes. Science 291(5507):1284–1289CrossRefPubMed
6.
Thompson LH, West MG (2000) XRCC1 keeps DNA from getting stranded. Mutat Res 459(1):1–18CrossRef
7.
Luo H, Li Z, Qing Y, Zhang SH, Peng Y, Li Q, Wang D (2014) Single nucleotide polymorphisms of DNA base-excision repair genes (APE1, OGG1 and XRCC1) associated with breast cancer risk in a Chinese population. Asian Pac J Cancer Prev 15(3):1133–1140CrossRefPubMed
8.
Yin G, Morita M, Ohnaka K, Toyomura K, Hamajima N, Mizoue T, Ueki T, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Yasunami Y, Maekawa T, Takenaka K, Ichimiya H, Terasaka R (2012) Genetic polymorphisms of XRCC1, alcohol consumption, and the risk of colorectal cancer in Japan. J Epidemiol 22(1):64–71CrossRefPubMedPubMedCentral
9.
Mei J, Duan HX, Wang LL, Yang S, Lu JQ, Shi TY, Zhao Y (2014) XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis. Tumour Biol 35(2):1221–1231CrossRefPubMed
10.
Bao Y, Jiang L, Zhou JY, Zou JJ, Zheng JY, Chen XF, Liu ZM, Shi YQ (2013) XRCC1 gene polymorphisms and the risk of differentiated thyroid carcinoma (DTC): a meta-analysis of case-control studies. PLoS One 8(5):e64851CrossRefPubMedPubMedCentral
11.
Letkova L, Matakova T, Musak L, Sarlinova M, Krutakova M, Slovakova P, Kavcova E, Jakusova V, Janickova M, Drgova A, Berzinec P, Halasova E (2013) DNA repair genes polymorphism and lung cancer risk with the emphasis to sex differences. Mol Biol Rep 40(9):5261–5273CrossRefPubMed
12.
Santonocito C, Scapaticci M, Penitente R, Paradisi A, Capizzi R, Lanza-Silveri S, Ficarra S, Landi F, Zuppi C, Capoluongo E (2012) Polymorphisms in base excision DNA repair genes and association with melanoma risk in a pilot study on central-south Italian population. Clin Chim Acta 413(19–20):1519–1524CrossRefPubMed
13.
Wang C, Ai Z (2014) Association of XRCC1 polymorphisms with thyroid cancer risk. Tumour Biol 35(5):4791–4797CrossRefPubMed
14.
Feng X, Miao G, Han Y, Xu Y, Wu H (2014) Glioma risks associate with genetic polymorphisms of XRCC1 gene in Chinese population. J Cell Biochem 115(6):1122–1127CrossRefPubMed
15.
He LW, Shi R, Jiang L, Zeng Y, Ma WL, Zhou JY (2014) XRCC1 gene polymorphisms and glioma risk in Chinese population: a meta-analysis. PLoS One 9(11):e111981CrossRefPubMedPubMedCentral
16.
Li J, Qu Q, Qu J, Luo WM, Wang SY, He YZ, Luo QS, Xu YX, Wang YF (2014) Association between XRCC1 polymorphisms and glioma risk among Chinese population. Med Oncol 31(10):186CrossRefPubMed
17.
Mei PJ, Bai J, Liu H, Li C, Wu YP, Yu ZQ, Zheng JN (2011) RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol 137(12):1823–1830CrossRefPubMed
18.
Fu XJ, Shi XJ, Lin K, Lin H, Huang WH, Zhang GJ, Au WW (2015) Environmental and DNA repair risk factors for breast cancer in South China. Int J Hyg Environ Health 218(3):313–318CrossRefPubMed
19.
Lamerdin JE, Montgomery MA, Stilwagen SA, Scheidecker LK, Tebbs RS, Brookman KW, Thompson LH, Carrano AV (1995) Genomic sequence comparison of the human and mouse XRCC1 DNA repair gene regions. Genomics 25(2):547–554CrossRefPubMed
20.
Sterpone, S. and Cozzi, R. (2010) Influence of XRCC1 Genetic Polymorphisms on Ionizing Radiation-Induced DNA Damage and Repair. J Nucleic Acids 2010
21.
Horton JK, Stefanick DF, Gassman NR, Williams JG, Gabel SA, Cuneo MJ, Prasad R, Kedar PS, DeRose EF, Hou EW, London RE, Wilson SH (2013) Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses. DNA Repair (Amst) 12(9):774–785CrossRef
22.
Barrows LR, Holden JA, Anderson M, D'Arpa P (1998) The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat Res 408(2):103–110CrossRefPubMed
23.
Wong HK, Wilson DM 3rd (2005) XRCC1 and DNA polymerase beta interaction contributes to cellular alkylating-agent resistance and single-strand break repair. J Cell Biochem 95(4):794–804CrossRefPubMed
24.
Liu D, Wu J, Shi GY, Zhou HF, Yu Y (2014) Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer. Genet Mol Res 13(2):3100–3107CrossRefPubMed
25.
Dai Q, Luo H, Li XP, Huang J, Zhou TJ, Yang ZH (2015) XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. Mutagenesis 30(3):441–449CrossRefPubMed
26.
Xu J, Ma J, Zong HT, Wang SY, Zhou JW (2014) Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis. Genet Mol Res 13(1):1438–1446CrossRefPubMed
27.
28.
Wang D, Hu Y, Gong H, Li J, Ren Y, Li G, Liu A (2012) Genetic polymorphisms in the DNA repair gene XRCC1 and susceptibility to glioma in a Han population in northeastern China: a case-control study. Gene 509(2):223–227CrossRefPubMed
29.
Hu XB et al (2011) Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to glioma. Asian Pac J Cancer Prev 12(11):2981–2984PubMed
30.
Bhandaru M, Martinka M, Li G, Rotte A (2014) Loss of XRCC1 confers a metastatic phenotype to melanoma cells and is associated with poor survival in patients with melanoma. Pigment Cell Melanoma Res 27(3):366–375CrossRefPubMed
31.
Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A, Lemoine NR (2002) Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21(29):4587–4594CrossRefPubMed
32.
Liu QH et al (2017) XRCC1 serves as a potential prognostic indicator for clear cell renal cell carcinoma and inhibits its invasion and metastasis through suppressing MMP-2 and MMP-9. Oncotarget 8(65):109382–109392PubMedPubMedCentral
33.
Sak SC et al (2005) APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 11(17):6205–6211CrossRefPubMed
34.
Wang S, Wu X, Chen Y, Zhang J, Ding J, Zhou Y, He S, Tan Y, Qiang F, Bai J, Zeng J, Gong Z, Li A, Li G, Roe OD, Zhou J (2012) Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res 18(10):2987–2996CrossRefPubMed
35.
Abdel-Fatah T, Sultana R, Abbotts R, Hawkes C, Seedhouse C, Chan S, Madhusudan S (2013) Clinicopathological and functional significance of XRCC1 expression in ovarian cancer. Int J Cancer 132(12):2778–2786CrossRefPubMed
36.
Ang MK, Patel MR, Yin XY, Sundaram S, Fritchie K, Zhao N, Liu Y, Freemerman AJ, Wilkerson MD, Walter V, Weissler MC, Shockley WW, Couch ME, Zanation AM, Hackman T, Chera BS, Harris SL, Miller CR, Thorne LB, Hayward MC, Funkhouser WK, Olshan AF, Shores CG, Makowski L, Hayes DN (2011) High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res 17(20):6542–6552CrossRefPubMedPubMedCentral
37.
38.
Lee MH, Yang HY (2003) Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 22(4):435–449CrossRefPubMed
39.
Costello JF et al (1996) Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56(10):2405–2410PubMed
40.
Koh I, Cha J, Park J, Choi J, Kang SG, Kim P (2018) The mode and dynamics of glioblastoma cell invasion into a decellularized tissue-derived extracellular matrix-based three-dimensional tumor model. Sci Rep 8(1):4608CrossRefPubMedPubMedCentral
41.
Fillmore HL, VanMeter TE, Broaddus WC (2001) Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neuro-Oncol 53(2):187–202CrossRef
42.
Anderson JC et al (2008) New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med e23:10
43.
Wurdinger T, Tannous BA (2009) Glioma angiogenesis: towards novel RNA therapeutics. Cell Adhes Migr 3(2):230–235CrossRef
44.
Guillamo JS, de Bouard S, Valable S, Marteau L, Leuraud P, Marie Y, Poupon MF, Parienti JJ, Raymond E, Peschanski M (2009) Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res 15(11):3697–3704CrossRefPubMed
45.
Cao Y, E G, Wang E, Pal K, Dutta SK, Bar-Sagi D, Mukhopadhyay D (2012) VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res 72(16):3912–3918CrossRefPubMedPubMedCentral
Metadata
Title
Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma
Authors
Peng-jin Mei
Jin Bai
Fa-an Miao
Zhong-lin Li
Chen Chen
Jun-nian Zheng
Yue-chao Fan
Publication date
01-08-2019
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2019
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-018-0667-9

Other articles of this Issue 4/2019

Investigational New Drugs 4/2019 Go to the issue

PHASE I STUDIES

Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial

PHASE II STUDIES

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

PHASE II STUDIES

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

PHASE I STUDIES

First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors

SHORT REPORT

Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis

PRECLINICAL STUDIES

Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits